Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings Plc, together with its subsidiaries, operates as a cancer diagnostics company in the United Kingdom. It develops a non-invasive blood test for early lung cancer detection using CIZ1B biomarker technology. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings … Read more
Cizzle Biotechnology Holdings PLC (CIZ) - Net Assets
Latest net assets as of June 2025: GBX-276.00K GBX
Based on the latest financial reports, Cizzle Biotechnology Holdings PLC (CIZ) has net assets worth GBX-276.00K GBX as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX257.00K) and total liabilities (GBX533.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX-276.00K |
| % of Total Assets | -107.39% |
| Annual Growth Rate | N/A |
| 5-Year Change | 156.25% |
| 10-Year Change | -96.59% |
| Growth Volatility | 697.46 |
Cizzle Biotechnology Holdings PLC - Net Assets Trend (2006–2024)
This chart illustrates how Cizzle Biotechnology Holdings PLC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cizzle Biotechnology Holdings PLC (2006–2024)
The table below shows the annual net assets of Cizzle Biotechnology Holdings PLC from 2006 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | GBX82.00K | -94.56% |
| 2023-12-31 | GBX1.51 Million | -42.92% |
| 2022-12-31 | GBX2.64 Million | +181.75% |
| 2021-12-31 | GBX937.00K | +2828.13% |
| 2020-12-31 | GBX32.00K | +382.58% |
| 2019-12-31 | GBX6.63K | +102.82% |
| 2018-12-31 | GBX-235.00K | -131.71% |
| 2017-12-31 | GBX741.00K | -66.12% |
| 2016-12-31 | GBX2.19 Million | -9.06% |
| 2015-12-31 | GBX2.40 Million | -52.35% |
| 2014-12-31 | GBX5.05 Million | +18.22% |
| 2013-12-31 | GBX4.27 Million | -10.93% |
| 2012-12-31 | GBX4.79 Million | +17.36% |
| 2011-12-31 | GBX4.08 Million | +15.30% |
| 2010-12-31 | GBX3.54 Million | +579.85% |
| 2009-12-31 | GBX521.00K | -68.73% |
| 2008-12-31 | GBX1.67 Million | -30.55% |
| 2007-12-31 | GBX2.40 Million | +4236.21% |
| 2006-12-31 | GBX-58.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cizzle Biotechnology Holdings PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 712300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX40.00K | 48.78% |
| Other Components | GBX10.08 Million | 12290.24% |
| Total Equity | GBX82.00K | 100.00% |
Cizzle Biotechnology Holdings PLC Competitors by Market Cap
The table below lists competitors of Cizzle Biotechnology Holdings PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Curative Biosciences Inc
PINK:CBDX
|
$750.15 |
|
House of Investments Inc
PSE:HI
|
$750.32 |
|
Dinewise Inc
PINK:DWIS
|
$750.98 |
|
Adia Nutrition Inc
PINK:ADIA
|
$752.96 |
|
CHAPEL HILL DENHAM NIG. INFRAS DEBT FUND
XNSA:NIDF
|
$746.00 |
|
Image Pakistan
KAR:IMAGE
|
$744.95 |
|
MacroAsia Corp
PSE:MAC
|
$744.84 |
|
ICU Girisim Sermayesi Yatirim Ortakligi A.S.
IS:ICUGS
|
$744.34 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cizzle Biotechnology Holdings PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,507,000 to 82,000, a change of -1,425,000 (-94.6%).
- Net loss of 2,166 reduced equity.
- New share issuances of 579,000 increased equity.
- Other comprehensive income increased equity by 29,462,000.
- Other factors decreased equity by 31,463,834.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-2.17K | -2.64% |
| Share Issuances | GBX579.00K | +706.1% |
| Other Comprehensive Income | GBX29.46 Million | +35929.27% |
| Other Changes | GBX-31.46 Million | -38370.53% |
| Total Change | GBX- | -94.56% |
Book Value vs Market Value Analysis
This analysis compares Cizzle Biotechnology Holdings PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8505.53x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | GBX-4.65 | GBX1.80 | x |
| 2007-12-31 | GBX80.59 | GBX1.80 | x |
| 2008-12-31 | GBX54.58 | GBX1.80 | x |
| 2009-12-31 | GBX11.39 | GBX1.80 | x |
| 2010-12-31 | GBX21.26 | GBX1.80 | x |
| 2011-12-31 | GBX13.96 | GBX1.80 | x |
| 2012-12-31 | GBX14.74 | GBX1.80 | x |
| 2013-12-31 | GBX11.61 | GBX1.80 | x |
| 2014-12-31 | GBX12.34 | GBX1.80 | x |
| 2015-12-31 | GBX0.02 | GBX1.80 | x |
| 2016-12-31 | GBX3.55 | GBX1.80 | x |
| 2017-12-31 | GBX1.06 | GBX1.80 | x |
| 2018-12-31 | GBX-0.11 | GBX1.80 | x |
| 2019-12-31 | GBX0.00 | GBX1.80 | x |
| 2020-12-31 | GBX0.00 | GBX1.80 | x |
| 2021-12-31 | GBX0.01 | GBX1.80 | x |
| 2022-12-31 | GBX0.01 | GBX1.80 | x |
| 2023-12-31 | GBX0.00 | GBX1.80 | x |
| 2024-12-31 | GBX0.00 | GBX1.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cizzle Biotechnology Holdings PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2.64%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 6.00x
- Recent ROE (-2.64%) is above the historical average (-115.34%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 0.00% | -654.50% | 0.24x | 0.00x | GBX-1.44 Million |
| 2007 | -77.74% | -607.49% | 0.10x | 1.30x | GBX-2.10 Million |
| 2008 | -80.55% | -82.43% | 0.73x | 1.34x | GBX-1.51 Million |
| 2009 | -70.83% | -23.64% | 1.32x | 2.27x | GBX-421.10K |
| 2010 | -25.01% | -32.57% | 0.54x | 1.43x | GBX-1.24 Million |
| 2011 | -25.07% | -16.89% | 0.99x | 1.49x | GBX-1.43 Million |
| 2012 | -16.27% | -8.96% | 1.07x | 1.70x | GBX-1.26 Million |
| 2013 | -15.25% | -6.91% | 1.28x | 1.73x | GBX-1.08 Million |
| 2014 | -26.39% | -18.53% | 0.92x | 1.56x | GBX-1.84 Million |
| 2015 | -115.05% | -40.10% | 1.35x | 2.12x | GBX-3.01 Million |
| 2016 | -0.01% | 0.00% | 1.18x | 2.05x | GBX-218.86K |
| 2017 | -0.02% | 0.00% | 1.47x | 4.16x | GBX-74.22K |
| 2018 | 0.00% | -2779.73% | 0.77x | 0.00x | GBX-2.03 Million |
| 2019 | -327.34% | 0.00% | 0.00x | 2.48x | GBX-22.37K |
| 2020 | -956.25% | 0.00% | 0.00x | 2.81x | GBX-309.20K |
| 2021 | -418.46% | 0.00% | 0.00x | 1.23x | GBX-4.01 Million |
| 2022 | -34.55% | 0.00% | 0.00x | 1.05x | GBX-1.18 Million |
| 2023 | -0.11% | 0.00% | 0.00x | 1.12x | GBX-152.42K |
| 2024 | -2.64% | 0.00% | 0.00x | 6.00x | GBX-10.37K |
Industry Comparison
This section compares Cizzle Biotechnology Holdings PLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $11,925,473
- Average return on equity (ROE) among peers: -149.92%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cizzle Biotechnology Holdings PLC (CIZ) | GBX-276.00K | 0.00% | N/A | $747.56 |
| 4BASEBIO UK SOCIETAS (4BB) | $11.70 Million | -27.66% | 0.26x | $10.53K |
| Aptamer Group PLC (APTA) | $8.05 Million | -26.00% | 0.43x | $3.12K |
| Arecor Therapeutics PLC (AREC) | $773.79K | -355.70% | 4.54x | $3.33K |
| Bioventix (BVXP) | $4.20 Million | 36.18% | 0.07x | $9.85K |
| Fusion Antibodies PLC (FAB) | $1.46 Million | 79.21% | 0.28x | $2.07K |
| Faron Pharmaceuticals Oy (FARN) | $1.61 Million | -823.73% | 5.34x | $27.00K |
| Futura Medical (FUM) | $9.72 Million | -50.98% | 0.21x | $424.60 |
| hVIVO plc (HVO) | $2.86 Million | -195.31% | 2.17x | $5.18K |
| International Biotechnology Trust plc (IBT) | $66.95 Million | 14.71% | 0.00x | $997.94 |